Current Status of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Review
Otolaryngology–Head and Neck Surgery · 2023-05 · 168 (5) · 988-1005
DOI: 10.1002/ohn.186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 19.01.2023. Verfasst von Sharmin Aktar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Molecular Pathology, School of Medicine and Dentistry, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Head and Neck Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 129 Literaturangaben.
Abstract (Originalsprache)
Objective
Circulating tumor cells (CTCs) are found in the blood of patients with cancer, including head and neck squamous cell carcinomas (HNSCCs). The aim is to review the most up‐to‐date status of CTCs for applications in patients with HNSCC. Data Sources English articles in PubMed. Review Methods All the studies on CTCs in HNSCCs in the literature were reviewed.
Conclusions
There is emerging information on the diagnostic and prognostic value of CTCs in HNSCCs. Evidence also highlights the advantages of various downstream analysis approaches over circulating tumor DNA (ctDNA), such as single‐CTC analysis, ex vivo, and in vivo expansion of CTCs. Multiple phenotypic surface markers (cytokeratins, EpCAM, vimentin, etc.), used for CTCs characterization using different immunoassays, could predict disease progression as well as patients' response to treatment efficacy. Immune checkpoint inhibitors' status in CTCs could also provide better insight into treatment. Clonal expansion of CTCs and single‐cell analysis of CTCs are the most emerging fields nowadays which may offer an understanding of the mechanism of tumor evolution as well as therapeutic efficacy. Although several clinical trials are ongoing, limitations still exist in the detection and characterization of CTCs. Due to the lack of a gold standard protocol, the sensitivity and specificity of CTC enumeration methods vary.
Implications for Practice
Prospective clinical trials are still needed before CTCs can be employed as diagnostic and prognostic markers in the clinical management of patients with HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Molecular Pathology, School of Medicine and Dentistry, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia.
- Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
- School of Dentistry, University of Queensland, Herston, Australia.
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh.
- Pathology Queensland, Gold Coast University Hospital, Southport, Australia.
ORCID-Profile: Alfred King-Yin Lam
Zitieren
APA
Aktar, S., Baghaie, H., Islam, F., Gopalan, V., & Lam, A. K. (2023). Current Status of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Review. Otolaryngology–Head and Neck Surgery, 168(5), 988-1005. https://doi.org/10.1002/ohn.186
Vancouver
Aktar S, Baghaie H, Islam F, Gopalan V, Lam AK. Current Status of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Review. Otolaryngology–Head and Neck Surgery. 2023;168(5):988-1005. doi:10.1002/ohn.186
BibTeX
@article{Aktar2023,
author = {Aktar, Sharmin and Baghaie, Hooman and Islam, Farhadul and Gopalan, Vinod and Lam, Alfred King-Yin},
title = {Current Status of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma: A Review},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
volume = {168},
number = {5},
pages = {988--1005},
doi = {10.1002/ohn.186}
}
EUVIMED